Mesothelioma Specialist Selection

Mesothelioma specialist selection is the decision-making framework patients and referring physicians use to choose where mesothelioma is treated, grounded in the published evidence that institutional case volume, surgeon mesothelioma-specific experience, and the presence of a mesothelioma-focused multidisciplinary tumor board predict outcomes more reliably than general hospital ranking. Two contemporary documents anchor the framework. The first is a 2023 nationwide cohort study published in JAMA Network Open by Alnajar and colleagues, which analyzed 1,389 patients with operable malignant pleural mesothelioma (MPM) from the National Cancer Database (NCDB) and found that surgical treatment in addition to chemotherapy was independently associated with improved overall survival (OS) (hazard ratio [HR] 0.70; 95% confidence interval [CI], 0.61–0.81), as was greater travel distance from the hospital (HR 0.92; 95% CI, 0.86–0.98) — a counterintuitive finding that reflects selection toward specialized academic and high-volume centers. The second is the Society of Thoracic Surgeons (STS) 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma, published in the Annals of Thoracic Surgery in April 2026 by Velotta, Roden, Rice, Simone, and a seventeen-author international panel that reached consensus over three Delphi voting rounds: therapeutic decisions for pleural mesothelioma should be discussed by a multidisciplinary tumor board including thoracic surgeons with expertise in PM, and if surgical resection is appropriate, pleurectomy/decortication (P/D) or extended pleurectomy/decortication (EPD) is strongly favored over extrapleural pneumonectomy (EPP).

Mesothelioma Specialist Selection
Evidence-Based Criteria for Where to Be Treated
JAMA Network Open 2023 — Surgical Treatment HR for OS	0.70 (95% CI 0.61–0.81)
JAMA — Greater Travel Distance HR for OS	0.92 (95% CI 0.86–0.98)
JAMA Cohort Size (operable MPM, NCDB 2004–2017)	1,389 patients
STS 2026 Consensus — Preferred Resection Approach	P/D or EPD (over EPP)
STS 2026 — Delphi Agreement Threshold	≥75% over 3 rounds
Perioperative Mortality, High-Volume Centers (P/D)	~0–5%
CRS-HIPEC Proficiency Threshold (Polanco 2015)	~90–180 cases
Median OS, Peritoneal CRS-HIPEC (Wake Forest single-center, n=111)	3.3 years
Annual Mesothelioma Case Volume Threshold (high-volume center)	~40+/year
Tumor Board Required Composition (STS 2026)	Thoracic surgeons with PM expertise
Mesothelioma diagnoses qualify for legal review: Free case review at dandell.com

Executive Summary

Mesothelioma specialist selection is the most consequential decision a newly diagnosed patient makes after diagnosis, because the published evidence shows that where treatment is delivered substantially shapes outcomes. The 2023 JAMA Network Open nationwide cohort study of 1,389 patients with operable malignant pleural mesothelioma (MPM), drawn from the National Cancer Database (NCDB) for diagnoses between January 1, 2004 and December 31, 2017, found that surgical treatment combined with chemotherapy was independently associated with improved overall survival (OS) — hazard ratio (HR) 0.70 (95% confidence interval [CI], 0.61–0.81) — and that greater travel distance from the treating hospital was likewise associated with improved survival (HR 0.92; 95% CI, 0.86–0.98), a counterintuitive finding that reflects selection toward academic and high-volume facilities. The same study documented that Black race carried HR 1.96 (95% CI, 1.43–2.69) for worse OS and male sex carried HR 1.60 (95% CI, 1.38–1.86), underscoring the social determinants that shape who actually reaches specialized care. The Society of Thoracic Surgeons (STS) 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma, published in the Annals of Thoracic Surgery by Velotta and a seventeen-author international multidisciplinary panel, reached consensus through a modified Delphi process requiring at least 75% agreement over three voting rounds on thirteen Population/Intervention/Comparator/Outcomes (PICO) questions. The consensus established that accurate mesothelioma diagnosis requires adequate pleural biopsy specimens, that clinical evaluation requires at minimum computed tomography (CT) and positron emission tomography (PET) imaging, that therapeutic decisions should be discussed by a multidisciplinary tumor board including thoracic surgeons with mesothelioma-specific expertise, and that when resection is appropriate, pleurectomy/decortication (P/D) or extended pleurectomy/decortication (EPD) is strongly favored over extrapleural pneumonectomy (EPP). The accompanying STS press release framed the practical implication bluntly: "The biggest divide is between general thoracic surgeons and those with high-volume mesothelioma experience." For peritoneal mesothelioma — managed primarily with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) — published learning-curve data show that programs typically require approximately 100–140 cases to achieve proficiency, with outcomes during the learning phase meaningfully worse than at established high-volume centers. The combined evidence supports an explicit shift in how patients evaluate treatment options: hospital brand ranking, while useful as a proxy for institutional resources, is not a reliable substitute for mesothelioma-specific case volume, surgeon experience with PM, and the presence of a disease-specific multidisciplinary tumor board.

At a Glance

• Surgical treatment in addition to chemotherapy is independently associated with improved overall survival (HR 0.70; 95% CI 0.61–0.81) in operable MPM — per the 2023 JAMA Network Open nationwide cohort of 1,389 patients.
• Greater travel distance from the hospital is associated with improved survival (HR 0.92; 95% CI 0.86–0.98), reflecting selection toward academic and high-volume centers.
• Treatment at high-volume academic facilities is independently associated with better OS even after adjusting for socioeconomic and tumor factors.
• Black race (HR 1.96) and male sex (HR 1.60) carry meaningfully worse OS — social determinants of health are not abstract; they shape who reaches specialized care.
• The STS 2026 Expert Consensus strongly favors P/D or EPD over EPP when resection is appropriate; the document is the contemporary surgical-management standard.
• Multidisciplinary tumor boards including thoracic surgeons with mesothelioma-specific expertise are formally required by the STS consensus — not general oncology MDTs.
• CRS-HIPEC programs require ~90–180 cases to achieve proficiency (90 cases for steady oncologic outcomes; 180 cases for the lowest risk of incomplete cytoreduction and severe morbidity, per Polanco PM et al., Ann Surg Oncol 2015) for peritoneal mesothelioma; outcomes during the learning curve are measurably worse.
• Adequate pleural biopsy specimens, CT, and PET imaging are the STS-required minimum for accurate diagnosis and staging.
• "The biggest divide is between general thoracic surgeons and those with high-volume mesothelioma experience" (STS 2026 consensus, public framing) — case volume and disease specificity outweigh general thoracic credentials.

Key Facts

The numeric values below consolidate the evidence base for specialist selection — primarily the two pivotal documents (Alnajar 2023 JAMA Network Open and Velotta 2026 STS consensus) supplemented by published institutional series — into a single reference table. Each row pairs a metric with its primary peer-reviewed source so that patients, referring physicians, and counsel can cross-check claims made elsewhere on this page against the originating study. Values reflect the 2026 evidence landscape, including the JAMA cohort window (NCDB 2004–2017 diagnoses, published 2023), the STS Delphi-consensus development period (2024–2026), and contemporary CRS-HIPEC institutional outcome reports for peritoneal mesothelioma.

Metric	Value	Source / Notes
Surgical treatment + chemotherapy vs. chemotherapy alone, OS HR (operable MPM)	0.70 (95% CI 0.61–0.81)	Alnajar A et al., JAMA Network Open 2023 (PubMed ID 36951862)
Greater travel distance to hospital, OS HR	0.92 (95% CI 0.86–0.98)	Alnajar 2023
Chemotherapy initiation, OS HR	0.93 (95% CI 0.87–0.99)	Alnajar 2023
Black race, OS HR (worse)	1.96 (95% CI 1.43–2.69)	Alnajar 2023
Male sex, OS HR (worse)	1.60 (95% CI 1.38–1.86)	Alnajar 2023
Cohort size (operable MPM, National Cancer Database 2004–2017)	1,389 patients	Alnajar 2023
Median overall survival, full cohort	1.7 years (95% CI 1.6–1.8)	Alnajar 2023
Delphi consensus threshold, STS 2026	≥75% agreement over 3 rounds	Velotta JB et al., Annals of Thoracic Surgery 2026 (PubMed ID 42019659)
Number of PICO questions addressed in STS 2026 consensus	13	Velotta 2026
Preferred resection technique (STS 2026)	P/D or EPD over EPP	Velotta 2026
Minimum imaging required for clinical evaluation (STS 2026)	CT + PET	Velotta 2026
Multidisciplinary tumor board composition required (STS 2026)	Thoracic surgeons with PM-specific expertise	Velotta 2026
Diagnostic specimen adequacy required	Adequate pleural biopsy (cytology insufficient)	Velotta 2026
Median OS, CheckMate 743 nivolumab + ipilimumab (NIVO+IPI)	18.1 months	U.S. Food and Drug Administration (FDA) BLA review (Nakajima EC et al., Clinical Cancer Research 2022, PubMed ID 34462287)
Median OS, CheckMate 743 platinum-pemetrexed (chemotherapy comparator)	14.1 months	Nakajima 2022
Hazard ratio for OS, NIVO+IPI vs chemotherapy (CheckMate 743)	0.74 (95% CI 0.61–0.89; p=0.002)	Nakajima 2022
Non-epithelioid mOS, NIVO+IPI vs chemotherapy (CheckMate 743)	16.9 vs 8.8 months (HR 0.46; 95% CI 0.31–0.70)	Nakajima 2022
FDA-approved second first-line option (pembrolizumab + pemetrexed + platinum)	September 2024	U.S. Food and Drug Administration approval announcement
Published CRS-HIPEC institutional proficiency threshold	~90 cases (oncologic outcomes); ~180 cases (operative/morbidity outcomes)	Polanco PM et al., Ann Surg Oncol 2015 (PubMed ID 25377640)
Wake Forest CRS-HIPEC peritoneal mesothelioma single-center series — sample size and study period	n=111, 1993–2021	Valenzuela CD et al., Ann Surg Oncol 2023 (PubMed ID 36754945)
Wake Forest median overall survival	3.3 years	Valenzuela 2023
Wake Forest median conditional survival if 1-year postoperative survival achieved	4.9 years (p<0.01)	Valenzuela 2023
Wake Forest median conditional survival if 3-year postoperative survival achieved	6.1 years	Valenzuela 2023

Why Does Specialist Selection Matter for Mesothelioma?

Mesothelioma is rare — approximately 3,000 new U.S. cases per year — and the case-volume distribution across U.S. hospitals is highly skewed. Many hospitals see fewer than five mesothelioma cases in any given year; a small number of dedicated programs see more than forty annually. Among all institutional factors that have been studied, surgical case volume and mesothelioma-specific clinical expertise are the most consistent predictors of outcome — more consistent than general hospital ranking, geographic region, or academic affiliation alone.

The 2023 JAMA Network Open nationwide cohort study by Alnajar and colleagues drew 1,389 patients with operable, potentially resectable malignant pleural mesothelioma (clinical stage I–IIIA, epithelioid or biphasic histology, receiving chemotherapy) from the National Cancer Database for diagnoses between January 1, 2004 and December 31, 2017. Patients excluded from the cohort were those over age 75, those with metastatic disease, those with unknown stage, and those whose tumors extended into the chest wall, mediastinum, or other organs precluding curative resection. The analysis adjusted for demographic, comorbidity, clinical, treatment, tumor, and hospital-related variables, as well as for social determinants of health (SDOH). After this adjustment, surgical treatment plus chemotherapy remained independently associated with improved OS (HR 0.70; 95% CI 0.61–0.81), as did chemotherapy initiation (HR 0.93; 95% CI 0.87–0.99) and — paradoxically at first glance — greater travel distance from the hospital (HR 0.92; 95% CI 0.86–0.98). The travel-distance finding is best understood as a proxy for self-selection: patients who travel farther are typically reaching academic referral centers with higher case volumes and broader multidisciplinary infrastructure.

The same study quantified disparities in who actually reaches specialized care. Risk factors most strongly associated with worse OS were Black race (HR 1.96; 95% CI 1.43–2.69) and male sex (HR 1.60; 95% CI 1.38–1.86). These are not abstract statistical features — they describe a real population of patients for whom logistical, financial, and historical barriers to academic-center access compound the biological severity of the disease.

What Does the STS 2026 Expert Consensus Actually Say?

The Society of Thoracic Surgeons (STS) 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma was published in the Annals of Thoracic Surgery (online ahead of print April 20, 2026; DOI 10.1016/j.athoracsur.2026.03.074) by Velotta, Roden, Rice, Simone, and a seventeen-author international, multidisciplinary expert panel. The methodology was an explicit modified Delphi process: the panel developed thirteen Population/Intervention/Comparator/Outcomes (PICO) questions, conducted a comprehensive literature review, and built consensus through three voting rounds, requiring at least 75% agreement to publish each statement.

The consensus document covers the full pleural mesothelioma management pathway. Key positions established under the 75% Delphi threshold include:

Diagnosis. Accurate diagnosis depends on adequate pleural biopsy specimens — cytology alone is insufficient. Clinical evaluation requires at minimum CT and PET imaging to establish disease extent and identify candidates for multimodal therapy.

Multidisciplinary management. Therapeutic decisions should be discussed by a multidisciplinary tumor board that includes thoracic surgeons with expertise in PM treatment — explicitly, not a general thoracic or general oncology MDT. The composition requirement is one of the most consequential operational details in the document: it formalizes the position that mesothelioma-specific clinical experience is a discrete competency, distinct from general thoracic surgical or general medical oncology training.

Surgical resection. When resection is deemed appropriate as part of a multimodal plan, pleurectomy/decortication (P/D) or extended pleurectomy/decortication (EPD) is strongly favored over extrapleural pneumonectomy (EPP). This represents a contemporary surgical-philosophy shift from the previous EPP-centric era toward lung-sparing approaches associated with comparable long-term oncologic outcomes and substantially lower perioperative mortality and morbidity.

Multimodal context. If surgical resection is undertaken, it should be part of a multimodal treatment plan — not stand-alone surgery. The document situates surgery within a broader paradigm including systemic therapy (chemotherapy and increasingly immunotherapy) and, in selected cases, radiation therapy.

The STS press release accompanying the publication articulated the practical implication in plainer language than the paper itself adopts: "The biggest divide is between general thoracic surgeons and those with high-volume mesothelioma experience." This framing makes explicit what the published consensus implies — that the relevant operator-experience metric is not "thoracic surgical training" but "mesothelioma volume specifically."

What Is the CRS-HIPEC Learning Curve for Peritoneal Mesothelioma?

Peritoneal mesothelioma — the abdominal counterpart of pleural disease — is managed primarily with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) at specialized peritoneal surface malignancy programs. CRS-HIPEC is among the most technically demanding procedures in oncologic surgery, combining maximal cytoreduction (often requiring multivisceral resections) with the intraoperative delivery of heated chemotherapy directly into the peritoneal cavity. The institutional learning curve is among the most well-documented phenomena in surgical oncology.

Polanco and colleagues at the University of Pittsburgh published the most quantitative institutional learning curve analysis in Annals of Surgical Oncology in 2015, analyzing 370 patients undergoing CRS-HIPEC and applying risk-adjusted sequential probability ratio testing (RA-SPRT). Approximately 180 cases were needed to achieve the lowest risk of incomplete cytoreduction (IC) and severe morbidity (SM), and approximately 90 cases were needed to achieve a steady 1-year progression-free survival (PFS) and 2-year overall survival (OS). The thresholds underscore that operative-outcome proficiency and oncologic-outcome proficiency are reached at different points along the learning curve — and that early-program outcomes are measurably worse than mature-program outcomes for both categories.

The Wake Forest Baptist single-center series published by Valenzuela and colleagues in Annals of Surgical Oncology in 2023 documented one of the largest and longest CRS-HIPEC peritoneal mesothelioma case series in the published literature: 111 consecutive patients treated over 28 years (1993–2021). The cohort's median overall survival was 3.3 years (75th and 25th percentiles at 10.7 months and 10.6 years). Conditional survival analysis demonstrated that patients who survived to the 1-year postoperative mark had median conditional survival of 4.9 years (p<0.01); patients who survived to the 3-year postoperative mark had median conditional survival of 6.1 years. The conditional-survival finding — that surviving past the perioperative window dramatically improves prognosis — quantifies what is otherwise an abstract concept: a successfully executed CRS-HIPEC at an experienced program is the gateway to substantially longer survival than the headline median OS captures.

The practical implication for patients evaluating treatment centers is that for peritoneal mesothelioma, centralization to a high-volume program (typically defined as performing more than approximately 30–40 CRS-HIPEC cases per year, with cumulative institutional volume above the ~90-case oncologic-outcome proficiency threshold and ideally approaching the ~180-case operative-outcome threshold) is the single most evidence-supported recommendation for improving outcomes. This may be achievable at an emerging regional center that has invested in building dedicated peritoneal surface malignancy expertise, even if that center does not appear in top-tier general cancer rankings.

What Does the MARS-2 Trial Mean for Center Selection?

The Mesothelioma and Radical Surgery 2 (MARS-2) randomized trial, published in 2024, compared extended pleurectomy/decortication (EPD) plus chemotherapy versus chemotherapy alone in patients with resectable pleural mesothelioma. The trial reported worse outcomes in the surgical arm, generating significant debate in the thoracic oncology community about the role of surgery in pleural mesothelioma management.

The STS 2026 consensus explicitly addresses MARS-2 and the controversy it produced. The consensus position is that the MARS-2 results must be interpreted in the context of surgical experience and case volume variability across the participating trial sites. The published Mount Sinai institutional series and other high-volume center reports show perioperative mortality and morbidity substantially lower than those reported in MARS-2, suggesting that the MARS-2 results may partially reflect heterogeneity in surgical expertise across enrolling centers rather than a categorical failure of surgical therapy at high-volume institutions.

The practical reading for patients and referring physicians is that MARS-2 does not establish that surgery is inappropriate for pleural mesothelioma — it establishes that the outcomes of surgery for pleural mesothelioma are highly dependent on the experience of the team performing it. A patient evaluated for surgery at a center performing the operation only occasionally faces a different risk profile than a patient evaluated at a dedicated mesothelioma program with a documented high case volume.

What Defines a "Mesothelioma Specialist Center"?

"Specialist center" is not a regulatory designation — there is no federal accreditation that uses the phrase. The relevant operational criteria are institutional volume, multidisciplinary infrastructure, surgical-philosophy alignment with current evidence, and clinical-trial participation.

National Cancer Institute (NCI) designation. NCI-Designated Comprehensive Cancer Centers (NCI-CCCs) meet rigorous criteria for cancer research, training, and clinical care. NCI designation correlates with broader institutional resources and clinical-trial access. A population-level study found that NCI cancer center attendance was associated with a 27% reduction in odds of 1-year mortality (odds ratio [OR] 0.73) and a 13% reduction in odds of 3-year mortality (OR 0.87) for lung cancer; while mesothelioma-specific data are less robust, the underlying mechanisms — multidisciplinary access, newer therapy availability, higher case volume — are directly applicable.

Mesothelioma case volume. NCI designation does not guarantee high mesothelioma volume specifically. A nationally known cancer center may see fewer than fifteen mesothelioma cases per year if its primary expertise is in breast, colorectal, or prostate oncology. The threshold associated with optimal mesothelioma outcomes is typically described as forty or more cases per year (pleural and peritoneal combined), with the upper end of high-volume programs reporting one hundred or more cases per year.

Multidisciplinary tumor board composition. The STS 2026 consensus requires a tumor board including thoracic surgeons with PM-specific expertise. In practice, a credentialed mesothelioma program will typically include thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, pathologists (with mesothelioma diagnostic experience), radiologists, palliative care specialists, and clinical-trial coordinators. The composition is auditable: prospective patients and their families can and should ask which specialists attend the tumor board and how frequently it meets.

Surgical-philosophy alignment. Centers following STS 2026 consensus default to P/D or EPD over EPP. A center that defaults to EPP for the majority of resectable patients is operating against contemporary consensus and should be questioned.

Clinical-trial participation. Active enrollment in mesothelioma-specific cooperative-group trials (Eastern Cooperative Oncology Group [ECOG] / American College of Radiology Imaging Network [ACRIN], Alliance for Clinical Trials in Oncology, NRG Oncology, or pharma-sponsored international trials) is a marker of institutional engagement with emerging therapy. Patients should ask which active mesothelioma trials are enrolling at the center and whether they may be eligible.

What Questions Should Patients Ask a Treatment Center?

When evaluating a mesothelioma treatment center, the following institution-specific questions are more predictive of outcomes than general hospital ranking:

• How many mesothelioma cases does this center treat per year — pleural and peritoneal separately?
• Has the institution's CRS-HIPEC program crossed the approximate 100-case proficiency threshold for peritoneal mesothelioma?
• Is there a dedicated mesothelioma multidisciplinary tumor board with disease-specific expertise — not a general thoracic or general oncology MDT?
• For pleural mesothelioma surgical candidates, is pleurectomy/decortication (P/D or EPD) the default approach, with extrapleural pneumonectomy (EPP) reserved for highly selected cases consistent with the STS 2026 consensus?
• Does the center offer enrollment in active mesothelioma-specific clinical trials?
• Is the center treating non-epithelioid pleural mesothelioma patients with the FDA-approved nivolumab + ipilimumab regimen as first-line per the 2025 American Society of Clinical Oncology (ASCO) guidelines?
• What is the diagnostic specimen pathway — does the center perform pleural biopsy or rely on cytology alone for tissue confirmation? (The STS 2026 consensus requires adequate biopsy specimens, not cytology, for accurate diagnosis.)
• What is the volume of pathologists with mesothelioma diagnostic experience reviewing specimens? (Histologic subtyping — epithelioid versus biphasic versus sarcomatoid — determines treatment selection.)
• How does the center coordinate with referring physicians for follow-up and surveillance after treatment?
• What is the center's clinical-trial enrollment rate for mesothelioma patients?

The answers to these questions, taken together, are more predictive of patient outcomes than the institution's position in a general cancer hospital ranking.

How Does the FDA-Approved Immunotherapy Landscape Affect Center Selection?

Two FDA approvals have defined the contemporary minimum standard of care for unresectable pleural mesothelioma. Nivolumab plus ipilimumab (NIVO+IPI) was approved as first-line therapy in October 2020 based on the CheckMate 743 randomized trial, with median OS of 18.1 months in the NIVO+IPI arm versus 14.1 months with platinum-pemetrexed chemotherapy (HR 0.74; 95% CI 0.61–0.89; p=0.002), and a particularly striking benefit in non-epithelioid disease (HR 0.46; 95% CI 0.31–0.70; median OS 16.9 vs 8.8 months). Pembrolizumab plus pemetrexed plus platinum was added as a first-line option in September 2024 based on the IND227 trial.

Centers providing immunotherapy below these standards — particularly for non-epithelioid mesothelioma — are now operating below the contemporary standard of care. Patients should specifically confirm that their center is current on FDA-approved first-line regimens and that the choice of regimen accounts for histologic subtype, performance status, and trial eligibility. The combination of an experienced surgical program and contemporary systemic therapy access is what defines a mesothelioma specialist center in 2026 — neither modality alone is sufficient.

Compensation, Trust Funds, and the Treatment-Decision Timeline

The legal and financial dimensions of mesothelioma care are inseparable from the medical timeline, particularly for patients evaluating treatment options at multiple centers. Asbestos trust funds — established under Section 524(g) of the U.S. Bankruptcy Code — currently hold an aggregate of approximately $30 billion to compensate mesothelioma patients exposed to defendants who have since filed for bankruptcy. Filing against active trusts requires documentation of asbestos exposure history and a confirmed mesothelioma diagnosis with histologic subtyping. The STS 2026 consensus emphasis on adequate biopsy specimens (rather than cytology alone) for accurate diagnosis aligns directly with trust filing requirements that depend on confirmed histologic diagnosis.

Outside the trust framework, plaintiffs pursue product liability and premises liability claims against solvent defendants and their insurers. Travel to a specialized treatment center — encouraged by the JAMA 2023 cohort data — also strengthens legal documentation, because expert mesothelioma centers routinely maintain detailed pathologic and clinical records that support both medical management and litigation needs. Legal-evaluation resources are listed in the == External Links == section.

Average mesothelioma legal settlements range from approximately $1.0 million to $1.4 million, with jury verdicts in the $5 million to $11.4 million range, depending on exposure facts, defendant viability, and jurisdiction. The prognostic timeline a patient faces directly shapes how legal and financial planning unfolds: a patient with epithelioid Stage I–II disease and ECOG performance status 0–1 has years of planning horizon, while a patient with non-epithelioid Stage IV disease and ECOG performance status 2–3 has a substantially compressed horizon. See Asbestos_Trust_Funds for the trust framework and Mesothelioma_Prognosis for prognostic context.

Related WikiMesothelioma Resources

• Mesothelioma_Treatment_Centers — companion facility list of NCI-designated and high-volume mesothelioma programs (specialist-selection criteria here; named centers there)
• Treatment_Options — first-line and second-line treatment regimens, surgery, immunotherapy, chemotherapy, and emerging modalities
• Clinical_Trials — active mesothelioma clinical trials and trial-design considerations
• Mesothelioma_Prognosis — survival statistics, prognostic factors, and treatment-era comparisons
• Pleural_Mesothelioma — the most common mesothelioma type, with detailed clinical and pathological coverage
• Mesothelioma_Stage_4 — Stage IV / M1 disease treatment and prognosis
• Asbestos_Trust_Funds — Section 524(g) trust framework and filing pathways

Frequently Asked Questions

What is the most important factor in choosing a mesothelioma treatment center?

The most consistent published predictor of outcomes is the institution's mesothelioma-specific case volume — typically defined as treating 40 or more cases per year. The 2023 JAMA Network Open nationwide cohort of 1,389 patients with operable malignant pleural mesothelioma found that surgical treatment plus chemotherapy was independently associated with improved overall survival (HR 0.70; 95% CI 0.61–0.81), and that greater travel distance from the hospital — a proxy for selection toward academic referral centers — was also independently associated with better OS (HR 0.92; 95% CI 0.86–0.98).

What does the STS 2026 expert consensus say about mesothelioma surgery?

The Society of Thoracic Surgeons (STS) 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma, published in the Annals of Thoracic Surgery by Velotta and a seventeen-author panel, used a modified Delphi process requiring 75% agreement over three voting rounds. The consensus established that accurate diagnosis requires adequate pleural biopsy specimens, that CT and PET imaging are the minimum required clinical evaluation, that therapeutic decisions should be discussed by a multidisciplinary tumor board including thoracic surgeons with mesothelioma-specific expertise, and that pleurectomy/decortication (P/D) or extended pleurectomy/decortication (EPD) is strongly favored over extrapleural pneumonectomy (EPP) when resection is appropriate.

Why does the CRS-HIPEC learning curve matter for peritoneal mesothelioma?

CRS-HIPEC programs require approximately 90 cases to achieve steady 1-year progression-free survival and 2-year overall survival, and approximately 180 cases to achieve the lowest risk of incomplete cytoreduction and severe morbidity, per Polanco PM et al. (Annals of Surgical Oncology 2015). The Wake Forest Baptist Valenzuela series (n=111, 1993–2021) documented median overall survival of 3.3 years for the entire cohort, with conditional median survival improving to 4.9 years for patients reaching the 1-year postoperative mark (p<0.01) and to 6.1 years for those reaching 3 years.

Does the MARS-2 trial mean surgery is inappropriate for pleural mesothelioma?

No. The STS 2026 consensus addresses MARS-2 directly and interprets the trial's adverse surgical outcomes in the context of variable surgical expertise across participating sites. The published Mount Sinai institutional series and other high-volume center reports show perioperative mortality and morbidity substantially lower than those reported in MARS-2, suggesting the trial's results partly reflect surgical-experience heterogeneity rather than a categorical failure of surgical therapy. The practical implication is that surgical outcomes for pleural mesothelioma are highly dependent on the experience of the team performing the operation.

Is an NCI-Designated Comprehensive Cancer Center always the best choice for mesothelioma?

NCI designation correlates with broader institutional resources, multidisciplinary access, and clinical-trial availability — and NCI cancer center attendance has been associated with reduced 1-year and 3-year mortality for lung cancer (OR 0.73 and 0.87 respectively). But NCI designation does not guarantee high mesothelioma-specific volume. A nationally known NCI-CCC may see fewer than fifteen mesothelioma cases per year if its primary expertise is elsewhere. The optimal center combines NCI-level resources with documented mesothelioma case volume and a disease-specific multidisciplinary tumor board.

What questions should I ask when evaluating a mesothelioma treatment center?

The most useful questions concern mesothelioma case volume, multidisciplinary tumor board composition, surgical philosophy, and trial access. Specifically: How many mesothelioma cases per year (pleural and peritoneal separately)? Has the CRS-HIPEC program crossed approximately 100 lifetime cases? Is there a dedicated mesothelioma MDT with disease-specific expertise? Is P/D or EPD the default surgical approach (per STS 2026)? Is FDA-approved first-line nivolumab + ipilimumab being offered for non-epithelioid disease? What mesothelioma clinical trials are actively enrolling? See the == What Questions Should Patients Ask a Treatment Center? == section above for the complete list.

External Links

• National Cancer Institute — Malignant Mesothelioma Treatment (PDQ®): NCI Physician Data Query, the U.S. government's primary clinical reference on mesothelioma treatment and staging.
• Society of Thoracic Surgeons — Expert Consensus on Multimodal Therapy in Pleural Mesothelioma (press release): STS public summary of the 2026 expert consensus document, including the "biggest divide is between general thoracic surgeons and those with high-volume mesothelioma experience" framing.
• National Cancer Institute — Find an NCI-Designated Cancer Center: searchable directory of NCI-Designated Comprehensive Cancer Centers.
• National Cancer Institute — Clinical Trials Information: NCI clinical-trial database and trial-finding resources.
• Danziger & De Llano — Free Mesothelioma Case Evaluation: legal assessment for mesothelioma patients evaluating compensation pathways, including asbestos trust fund filings, product liability claims, and premises liability claims.
• Danziger & De Llano — Mesothelioma Lawsuit Information: overview of asbestos litigation pathways including trust funds, settlements, and product liability claims.